IQ-AI Limited (IQAI) RNS Announcements

Add to Alert list
Date Time Source Announcement
05 Nov 2024 07:00 AM
RNS
New Patent Application and Trading Update
15 Oct 2024 10:28 AM
RNS
Holding(s) in Company
15 Oct 2024 07:00 AM
RNS
IQ-AI Issues Letter to Shareholders
14 Oct 2024 12:08 PM
RNS
Holding(s) in Company
14 Oct 2024 12:05 PM
RNS
PDMR dealing and TR1 announcement
11 Oct 2024 10:42 AM
RNS
Acquisition of Interest by Braveheart
13 Aug 2024 02:53 PM
RNS
Half-year Report
25 Jun 2024 09:59 AM
RNS
IB Opens Expanded Access Program
14 Jun 2024 08:38 AM
RNS
Clinical Trial Updates
29 May 2024 03:08 PM
RNS
Result of AGM
23 May 2024 07:00 AM
RNS
Major East Coast Health System Chooses IB Nimble
20 May 2024 07:10 AM
RNS
Second FDA Rare Pediatric Disease Designation
17 May 2024 07:00 AM
RNS
IB Software Enhances Clinical Decision-Making
10 May 2024 08:15 AM
RNS
Rare Pediatric Disease Designation Granted to GaM
02 May 2024 12:47 PM
RNS
IB Announces Expanded Access Program for GaM
29 Apr 2024 03:26 PM
RNS
Publication of Annual Report
05 Mar 2024 07:00 AM
RNS
Grant of Options
01 Mar 2024 08:22 AM
RNS
Holding(s) in Company
01 Mar 2024 08:20 AM
RNS
Holding(s) in Company
26 Feb 2024 07:00 AM
RNS
Result of Broker Option and Total Voting Rights
22 Feb 2024 07:00 AM
RNS
Placing and Broker Option
09 Feb 2024 12:49 PM
RNS
FDA Application Update
02 Feb 2024 08:39 AM
RNS
IB awarded a $100,000 grant
02 Feb 2024 08:39 AM
RNS
IB awarded a $100,000 grant
22 Jan 2024 10:05 AM
RNS
Holding(s) in Company
15 Jan 2024 07:01 AM
RNS
Director Dealings and Conversion of CLNs
15 Jan 2024 07:00 AM
RNS
Holding(s) in Company
10 Jan 2024 07:00 AM
RNS
IB Launching an Expanded Access Program for GaM
19 Dec 2023 02:29 PM
RNS
Imaging Biometrics granted FDA “Fast-Track”
05 Dec 2023 10:58 AM
RNS
IQ-AI Announces Positive Interim Phase 1 Results
20 Nov 2023 01:42 PM
RNS
Holding(s) in Company
09 Nov 2023 11:38 AM
RNS
Director Dealing and Conversion of CLNs
08 Nov 2023 10:59 AM
RNS
Application for Pediatric Rare Disease Designation
06 Nov 2023 01:02 PM
RNS
Holding(s) in Company
18 Oct 2023 02:29 PM
RNS
Update Regarding Imaging Biometrics LLC
13 Oct 2023 08:55 AM
RNS
IB Letter to Shareholders
09 Oct 2023 07:00 AM
RNS
Orphan Drug Status to GaM and Total Voting Rights
03 Oct 2023 11:30 AM
RNS
Holding(s) in Company
19 Sep 2023 02:32 PM
RNS
IQ-AI shares cease trading on the OTCQB
08 Sep 2023 07:00 AM
RNS
Reduced Gadolinium Approach Validated'
18 Aug 2023 12:06 PM
RNS
Update on Collaboration Agreement with Mayo Clinic
18 Aug 2023 11:20 AM
RNS
IB & GE HealthCare Enter into Commercial Agreement
17 Aug 2023 07:00 AM
RNS
Half-year Report
19 Jul 2023 07:00 AM
RNS
Imaging Biometrics Installs IB Nimble™ For MCW
13 Jul 2023 07:00 AM
RNS
Orphan Drug Designation for GaM in Pediatric GBM
27 Jun 2023 07:00 AM
RNS
Studies Show GaM Inhibits Pediatric Tumor Growth
23 May 2023 11:02 AM
RNS
Result of AGM
23 May 2023 07:00 AM
RNS
AGM Statement
03 May 2023 04:14 PM
RNS
Notice of AGM
26 Apr 2023 07:00 AM
RNS
Final Results

IQ-AI Ltd operates as an investment company. The principal activity of the group is the provision of convenient, cost-effective, and clinical treatments to patients in the field of medical imaging diagnostics, based on proven technologies. Its geographical segment includes Jersey and the United States of America and reportable segments are holding company expenses and medical software. The company derives a majority of revenue from the United States of America. It also supplies medical technology solutions and has a strong neuroimaging product portfolio.

IQ-AI share price listed in London at 87p in 1996.

UK 100

Latest directors dealings